All In Biotech

Drug Trial Radar · NCT06344715

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

A Phase 1, Multi-center, Open-label, Dose-escalating Study to Evaluate the Safety and Tolerability of Triple Combination Regimen of SL-T10, GX-I7 and Pembrolizumab in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

78

Planned (sponsor's estimate)

Start

Oct 17, 2022

Primary completion

Oct 31, 2024

Study completion Oct 31, 2024

Sponsor

Lead sponsor
SL VAXiGENIndustry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

  • SL-T10Biological

    A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

  • GX-I7Biological

    A T-cell growth factor

  • PembrolizumabBiological

    An immune check point inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Baseline to 23 weeks
  2. Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0Time frame: Baseline to 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.